1
|
Barrientos-Rios R, Frias S, Velázquez-Aragón JA, Villaroel CE, Sánchez S, Molina B, Martínez A, Carnevale A, García-de-Teresa B, Bonilla E, Alvarado-Araiza CD, Valderrama-Hernández A, Ríos-Gallardo PT, Calzada-León R, Altamirano-Bustamante N, Torres L. Low bone mineral density and renal malformation in Mexican patients with Turner syndrome are associated with single nucleotide variants in vitamin D-metabolism genes. Gynecol Endocrinol 2019; 35:772-776. [PMID: 30887870 DOI: 10.1080/09513590.2019.1582626] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Turner syndrome (TS) is a common genetic disorder. TS-phenotype includes short stature, gonadal dysgenesis, cardiac and kidney malformations, low bone mineral density (low-BMD) and thyroiditis. TS-phenotype varies from patient to patient and the cause is not clear, the genomic background may be an important contributor for this variability. Our aim was to identify the association of specific single nucleotide variants in the PTPN22, VDR, KL, and CYP27B1 genes and vitamin D-metabolism, heart malformation, renal malformation, thyroiditis, and low-BMD in 61 Mexican TS-patients. DNA samples were genotyped for SNVs: rs7975232 (VDR), rs9536282 (KL), rs4646536 (CYP27B1), and rs1599971 (PTPN22) using the KASP assay. Chi-square test under a recessive model and multifactorial dimensionality reduction method were used for analysis. We found a significant association between renal malformation and the rs9536282 (KL) variant and between rs4646536 (CYP27B1) and low-BMD, these variants may have modest effects on these characteristics but contribute to the variability of the TS phenotype. In addition, we identified gene-gene interactions between variants in genes KL, CYP27B1 and VDR related to vitamin D-metabolism and low-BMD in TS-patients. Our results support the idea that the genetic background of TS-patients contributes to the clinical variability seen in them.
Collapse
Affiliation(s)
- Rehotbevely Barrientos-Rios
- a Laboratorio de Citogenética, Departamento de Genética Humana, Instituto Nacional de Pediatría , Ciudad de México , Mexico
- b Posgrado en Biología Experimental, Universidad Autónoma Metropolitana , Ciudad de México , Mexico
| | - Sara Frias
- a Laboratorio de Citogenética, Departamento de Genética Humana, Instituto Nacional de Pediatría , Ciudad de México , Mexico
- c Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México , Ciudad de México , Mexico
| | - José A Velázquez-Aragón
- d Laboratorio de Biología Molecular, Departamento de Genética Humana, Instituto Nacional de Pediatría , Ciudad de México , Mexico
| | - Camilo E Villaroel
- e Departamento de Genética Humana, Instituto Nacional de Pediatría , Ciudad de México , Mexico
| | - Silvia Sánchez
- a Laboratorio de Citogenética, Departamento de Genética Humana, Instituto Nacional de Pediatría , Ciudad de México , Mexico
| | - Bertha Molina
- a Laboratorio de Citogenética, Departamento de Genética Humana, Instituto Nacional de Pediatría , Ciudad de México , Mexico
| | - Angélica Martínez
- f Departamento de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica , Ciudad de México , Mexico
| | - Alessandra Carnevale
- g Laboratorio de Enfermedades Mendelianas, Instituto Nacional de Medicina Genómica , Ciudad de México , Mexico
| | - Benilde García-de-Teresa
- a Laboratorio de Citogenética, Departamento de Genética Humana, Instituto Nacional de Pediatría , Ciudad de México , Mexico
| | - Edmundo Bonilla
- b Posgrado en Biología Experimental, Universidad Autónoma Metropolitana , Ciudad de México , Mexico
| | | | | | | | - Raúl Calzada-León
- h Servicio de Endocrinología, Instituto Nacional de Pediatría , Ciudad de México , Mexico
| | | | - Leda Torres
- a Laboratorio de Citogenética, Departamento de Genética Humana, Instituto Nacional de Pediatría , Ciudad de México , Mexico
| |
Collapse
|
2
|
Patterson AD, Bonzo JA, Li F, Krausz KW, Eichler GS, Aslam S, Tigno X, Weinstein JN, Hansen BC, Idle JR, Gonzalez FJ. Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem 2011; 286:19511-22. [PMID: 21487016 PMCID: PMC3103330 DOI: 10.1074/jbc.m111.221739] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2011] [Revised: 04/08/2011] [Indexed: 01/15/2023] Open
Abstract
To enhance understanding of the metabolic indicators of type 2 diabetes mellitus (T2DM) disease pathogenesis and progression, the urinary metabolomes of well characterized rhesus macaques (normal or spontaneously and naturally diabetic) were examined. High-resolution ultra-performance liquid chromatography coupled with the accurate mass determination of time-of-flight mass spectrometry was used to analyze spot urine samples from normal (n = 10) and T2DM (n = 11) male monkeys. The machine-learning algorithm random forests classified urine samples as either from normal or T2DM monkeys. The metabolites important for developing the classifier were further examined for their biological significance. Random forests models had a misclassification error of less than 5%. Metabolites were identified based on accurate masses (<10 ppm) and confirmed by tandem mass spectrometry of authentic compounds. Urinary compounds significantly increased (p < 0.05) in the T2DM when compared with the normal group included glycine betaine (9-fold), citric acid (2.8-fold), kynurenic acid (1.8-fold), glucose (68-fold), and pipecolic acid (6.5-fold). When compared with the conventional definition of T2DM, the metabolites were also useful in defining the T2DM condition, and the urinary elevations in glycine betaine and pipecolic acid (as well as proline) indicated defective re-absorption in the kidney proximal tubules by SLC6A20, a Na(+)-dependent transporter. The mRNA levels of SLC6A20 were significantly reduced in the kidneys of monkeys with T2DM. These observations were validated in the db/db mouse model of T2DM. This study provides convincing evidence of the power of metabolomics for identifying functional changes at many levels in the omics pipeline.
Collapse
Affiliation(s)
| | - Jessica A. Bonzo
- From the Laboratory of Metabolism, Center for Cancer Research, and
| | - Fei Li
- From the Laboratory of Metabolism, Center for Cancer Research, and
| | | | - Gabriel S. Eichler
- the Genomics and Bioinformatics Group, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
| | - Sadaf Aslam
- the Departments of Internal Medicine and Pediatrics, University of South Florida, Tampa, Florida 33612, and
| | - Xenia Tigno
- the Departments of Internal Medicine and Pediatrics, University of South Florida, Tampa, Florida 33612, and
| | - John N. Weinstein
- the Genomics and Bioinformatics Group, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
| | - Barbara C. Hansen
- the Departments of Internal Medicine and Pediatrics, University of South Florida, Tampa, Florida 33612, and
| | - Jeffrey R. Idle
- the Department of Clinical Pharmacology, University of Bern, Bern 3010, Switzerland
| | | |
Collapse
|